Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

BALTIMORE, May 21 /PRNewswire/ -- Alba Therapeutics Corporation announced today that data from its Phase IIa clinical trial were presented in the Clinical Advances in Celiac Disease session at the Digestive Disease Week (DDW) meeting in San Diego, California. Results of the randomized, double- blind, placebo controlled study of larazotide acetate for the prevention of celiac disease reactivation by gluten challenge in celiac subjects in remission(1) were presented by Daniel Leffler, MD from Beth Israel Deaconess Medical Center at the DDW today.

Celiac disease affects approximately 1% of individuals in the United States and Europe or approximately 6.5 million individuals. The only accepted therapy for the disease is a strict gluten-free diet; however, the response to therapy is poor or incomplete in up to 30% of patients. Dietary non-adherence is the chief cause of persistent or recurrent symptoms(2). Over time, 30-50% of individuals are unable to maintain a strict gluten-free diet. Additionally, a gluten-free diet fails to induce clinical or histological improvement in 7-30% of celiac patients and such a lack of response should trigger a systematic evaluation(3). These facts suggest that there is a need for therapeutic modalities beyond dietary modification.

Alba's study, the first Phase IIa trial in celiac disease and the first to assess dosing requirements for larazotide acetate, was designed to evaluate the safety, tolerability and efficacy of multiple doses of larazotide acetate in celiac disease subjects during a 2 week gluten challenge. The randomized, double-blind, placebo-controlled clinical trial enrolled 86 patients who had a confirmed biopsy diagnosis for celiac disease and were in compliance with a gluten-free diet for at least six months prior to enrollment as demonstrated by a negative serology test of anti-transglutaminase (tTG). Patients were randomized into seven drug-treated and placebo groups and challenged three times a day w
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)...  Lakeland Industries, Inc. (NASDAQ: LAKE ... clothing for industry, municipalities, healthcare and first responders ... announced that the Company accepted a commitment letter ... subject to certain terms and conditions and is ... assurances can be given that this transaction or ...
(Date:5/21/2013)... 21 de mayo de 2013 La junta ... filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. y Praxim, ... su junta. Guy Mayer, un ejecutivo ortopédico experimentado, será ... David Johnson , un experto refutado en ... Antes de unirse a OSI como presidente de ...
(Date:5/21/2013)... CINCINNATI , May 21, 2013  LCA-Vision Inc. (NASDAQ: ... correction services under the Lasik Plus ® brand, announces that ... to one-year terms at today,s annual meeting of stockholders.  These ... , co-founder and President of Bahl & Gaynor Investment Counsel ... with BSC Ventures , Edgar F. Heizer ...
Breaking Medicine Technology:Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 2Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 3Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 4Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 5Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 6Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 7Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 8Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 9Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 10Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 11Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 12Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 13Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4
... 4Q07/1Q08, DALLAS, Aug. 20 Access Pharmaceuticals, ... on the clinical,development plan of ProLindac, its novel ... human clinical trials to be initiated in,late 2007/ ... ovarian,cancer patients, designed to optimize single agent dosing ...
... in the journal Blood found 92 percent reduction in ... ... Patients with a rare,blood disorder called PNH experienced a ... following treatment,with Soliris(TM) (eculizumab), according to an analysis of clinical ...
Cached Medicine Technology:Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 2Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 3Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8
(Date:5/22/2013)... Asthma, a disorder that causes the airways ... shortness of breath, chest tightness and coughing without sputum ... the airways become tight and the lining of the ... can pass. Asthma attacks can last for minutes to ... Reuters reports that there is a link ...
(Date:5/22/2013)... 22, 2013 Poor adherence to appropriate ... only medical complications and death (some 125,000 deaths in ... but increased health-care costs. It’s been estimated that between ... related to poor medication adherence — a reality that ... , Indeed, so dire is the degree of medication ...
(Date:5/22/2013)... Those who have already gone through a ... the hardest work is yet to come. As of April ... patients have special health needs that should be addressed in ... Lap-Band Surgery” abclocal.go.com/kabc/story?section=news/food_coach&id=9078455). Bariatric surgeon Dr. Madan offers four tips ... weight can be lost and kept off. , First, ...
(Date:5/22/2013)... SAN DIEGO, CA (PRWEB) May 22, 2013 ... active lifestyle media and publishing company released today ... The 10 healthiest business hotels received the company’s ... traveler feedback, and anonymous personal tours by the ... multi-sport options (e.g., lap pool, sport court, etc.), ...
(Date:5/21/2013)... The University of Colorado’s Anschutz Health and ... to help Coloradans make healthier choices when they eat ... called HEALTHY DINING IN COLORADO. More than 40 ... Colorado. Restaurants will offer a selection of dietitian verified ... vegetables, fruits, whole grains and unsaturated fats. , “Families ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce New hCG Diet Plans That May Reduce the Severity of Asthma Attacks 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce New hCG Diet Plans That May Reduce the Severity of Asthma Attacks 3Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2Health News:The Lap Band Center: Dr. Atul Madan Offers Five Tips for Ongoing Weight Loss for Lap Band Patients 2Health News:The Lap Band Center: Dr. Atul Madan Offers Five Tips for Ongoing Weight Loss for Lap Band Patients 3Health News:2013: The 10 Healthiest Business Hotels in the U.S. 2Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 2Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 3
... could offer clues to effects of aging, experts say ... that plays an important role in coordinating people,s circadian ... , The circadian clock governs daily cycles of ... University and the Washington University School of Medicine said ...
... ,Celebrating case reports, the stories in health care, will be ... 15 May this year, and will bring together leading doctors ... the Editors of Cases Network,s journals Richard Smith (the ... University, Australia). , Richard Smith said of Cases Network,s goal, ...
... Annual American Academy of Dermatology MeetingCRANFORD, N.J., March 19 ... Lipocream(R) (hydrocortisone butyrate 0.1%) the leading mid-potency corticosteroid ... recently launched Locoid(R) Lotion . ... Dermatology (AAD) meeting in San Francisco, ...
... The "Help is Here Express" bus tour will be ... various cities throughout the state in order to help ... provide prescription medicines for free or nearly free. With ... months, and having passed the national unemployment rate (7.6 ...
... Pa., March 19 eHealth specialist InterComponentWare (ICW) has ... at the IHE North American Connectathon, the only large-scale ... the past three years the interoperability of ICW,s Master ... conformant. The interoperability of the ICW MPI succeeded ...
... 19 VNUS Medical Technologies, Inc. (Nasdaq: VNUS ... invasive treatment of venous reflux disease, today announced its plans ... Growth Institutional Investor Forum, to be held March 24 - ... City. The management speaker will be Peter Osborne, Chief ...
Cached Medicine News:Health News:Internal Clock and Metabolism May Be Linked 2Health News:Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potency Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1% 2Health News:Partnership for Prescription Assistance Prepared to Help Georgia Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Georgia Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Georgia Workers Hurt by Recession 4Health News:ICW Master Patient Index Passes HITSP Certification and IHE Tests 2
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
Medicine Products: